Cardiovascular
FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP
July 1, 2010 5:35 am | by Bio-Medicine.Org | News | CommentsSCHAUMBURG, Ill. , July 1 /- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's nine presentations of heparin sodium injection, USP. Heparin is a vital anticoagulant,...
BIO Announces Livestock Biotech Summit Preliminary Program
June 29, 2010 10:37 am | by Biotechnology Industry Organization | News | CommentsWASHINGTON, D.C. (Tuesday, June 29, 2010) -Â The Biotechnology Industry Organization (BIO) today announces the preliminary program for the 2010 Livestock Biotech Summit which will provide participants three days of cross-cutting discussions among industry, academic and government leaders....
Award-Winning Thermal Angel Selected as Winner for 'Outstanding Military Product of the Year'
June 29, 2010 10:37 am | by Bio-Medicine.Org | News | CommentsDALLAS , June 29 /PRNewswire-USNewswire/ -- The Thermal Angel Blood and IV Fluid Infusion Warmer , a patented medical device being utilized by U.S. hospitals , military and emergency responders around the globe to lessen the effects of fluid-induced hypothermia, was named the winner for...
Vermillion Announces Issuance of Patent for Alzheimer's Disease Diagnosis
June 29, 2010 7:36 am | by Bio-Medicine.Org | News | CommentsFREMONT, Calif. , June 29 /- Vermillion, Inc. (Pink Sheets: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company. The...
BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG
June 29, 2010 7:35 am | by Bio-Medicine.Org | News | CommentsTEL AVIV, Israel , June 29, 2010 /- BSP, which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, announced today that its Add-On product, the HyperQ AD-100 ( http://www.bsp.co.il/pdf/HyperQ AD-100 Pic.pdf), intended for improved...
Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company
June 28, 2010 10:36 am | by Bio-Medicine.Org | News | CommentsCASTRES, France , June 28, 2010 /- Mr Jean-Pierre Garnier will step down on September 1st 2010, two years after having been appointed CEO of the Pierre Fabre Group. "The Company is in excellent health, and is poised to experience a bright future ; I am glad to have contributed to its...
Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients
June 28, 2010 10:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 28 /- Today Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (ADA) 2010...
New Data Demonstrates Victoza® (liraglutide rDNA injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at On...
June 28, 2010 6:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 28 /- Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza ® in combination with metformin produced sustained and...
New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
June 28, 2010 6:36 am | by Bio-Medicine.Org | News | CommentsPARSIPPANY, N.J. , June 28 /- Preliminary results of a pre-specified subgroup study analysis of patients with diabetes and hypertension demonstrated that the investigational triple combination therapy of olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) resulted in a...
Building a Substitute Pancreas for Diabetics
June 27, 2010 8:38 pm | by Massachusetts Institute of Technology | News | CommentsA startup hopes implanted insulin-producing cells will free diabetics from insulin injections.
New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
June 26, 2010 9:37 am | by Bio-Medicine.Org | News | CommentsPARSIPPANY, N.J. , June 26 /- Results of a new study demonstrated that initial combination therapy with Welchol® (colesevelam HCl) 3.75 g/d and metformin (initiated at 850 mg/d; uptitrated to 1700 mg/d thereafter) significantly improved glycemic and lipid control in drug-naive adult...
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26, 2010 /- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on...
New Data Demonstrates Victoza® (liraglutide rDNA injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52...
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26 /- Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and...
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26 /- Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose...
Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26 /- An estimated 75 percent of adults with type 1 and type 2 diabetes say they believe they know what their blood sugar levels are without testing, according to data presented at the American Diabetes Association (ADA) 70th Scientific Sessions. These results are...
HeartWare names Larkin as board chairman
June 25, 2010 7:35 am | by Mass High Tech: The Journal of New England Technology | News | CommentsHeartWare International Inc., a Framingham maker of heart devices, has appointed board member C. Raymond Larkin, Jr. to the role of chairman of the board.
Phase 1 trial triggers $1M payment for ImmunoGen
June 25, 2010 5:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsBiotech firm ImmunoGen Inc. is in line for a $1 million milestone payment from sanofi-aventis, now that sanofi has launched a Phase 1 clinical trial of ImmunoGen's SAR650984 investigational antibody.
Alnylam's Maraganore joins Agios board
June 24, 2010 10:36 am | by Mass High Tech: The Journal of New England Technology | News | CommentsAgios Pharmaceuticals Inc., a Cambridge biopharmaceutical focused on the field of cancer metabolism, has named John Maraganore, CEO of Alnylam Pharmaceuticals, to its board of directors.
Attenda underpins the infrastructure for Microsoft HealthVault UK launch
June 23, 2010 1:33 am | by RealWire | News | CommentsLondon - June 23, 2010 - Attenda Limited, the Always On Managed Services company, today announced that it had reached an agreement with Microsoft for support in the UK of Microsoft HealthVault, a privacy and security-enhanced, cloud-based platform that enables individuals to store, share...
Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes
June 22, 2010 6:35 am | by Bio-Medicine.Org | News | CommentsINDIANAPOLIS and BENTONVILLE, Ark. , June 22 /- Walmart (NYSE: WMT ) and Eli Lilly and Company (NYSE: LLY ) announced today they're teaming up to provide an affordable insulin option for people with diabetes. Beginning in mid-September, Lilly's Humulin ® brand of insulin will...
Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
June 22, 2010 6:34 am | by Bio-Medicine.Org | News | CommentsIRVINE, Calif. , June 22 /- Cardiogenesis Corporation (OTCQB: CGCP) today announced that its shares are now being quoted on the newly launched OTCQB™ market. Launched in April 2010 , the OTCQB is a new market tier for OTC-traded U.S. companies that are registered and reporting with...
MedGadget's MedTech Monday: Custom-fit degradable cranial implant
June 21, 2010 8:35 am | by Mass Device | News | CommentsA custom-fit degradable implant for filling bone defects after craniofacial surgery; a study shows Bard's LifeStent as superior to stentless angioplasty; Micrus' DeltaPAQ and DeltaPlush microcoils cleared in Japan; and CorMatrix's cardiac tissue repair wins CE Mark. ...
Cardiovascular Devices Market Outlook June Update by ReportsandReports
June 21, 2010 4:37 am | by Bio-Medicine.Org | News | CommentsDALLAS , June 21, 2010 /- ReportsandReports announces it Will Carry Cardiovascular Devices Market Outlook 2016 June reports in its store. Netherlands Cardiovascular Devices Market Outlook to 2016 ( http://www.reportsandreports.com/market-reports/netherlands-cardiovascul......
California Cryobank Welcomes New Director of Quality/Regulatory Affairs
June 21, 2010 4:37 am | by Bio-Medicine.Org | News | CommentsLOS ANGELES , June 21 /- California Cryobank (CCB), a worldwide leader in biotechnology services, is proud to announce the recent hiring of Rama Tyagi as the company's Director of Quality/Regulatory Affairs. Tyagi's hiring into the newly created position echoes CCB's ongoing commitment to...
Boston Scientific Expands PolarCath® Peripheral Dilatation System With New Balloon Sizes
June 21, 2010 4:36 am | by Boston Scientific | News | CommentsLonger balloons provide physicians more options for treating peripheral artery disease
